Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders

MLA

Mallinckrodt, Craig H., et al. “Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders.” Drug Information Journal, vol. 44, no. 4, July 2010, pp. 421–30. EBSCOhost, https://doi.org/10.1177/009286151004400406.

APA

Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., & Molenberghs, G. (2010). Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders. Drug Information Journal, 44(4), 421–430. https://doi.org/10.1177/009286151004400406

Chicago

Mallinckrodt, Craig H., Michael J. Detke, William R. Prucka, Stephen J. Ruberg, and Geert Molenberghs. 2010. “Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders.” Drug Information Journal 44 (4): 421–30. doi:10.1177/009286151004400406.